Patents Assigned to Acuitas Therapeutics Inc.
-
Patent number: 12151996Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, G1, G2, and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: July 11, 2022Date of Patent: November 26, 2024Assignee: Acuitas Therapeutics, Inc.Inventor: Xinyao Du
-
Patent number: 12129223Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: December 15, 2022Date of Patent: October 29, 2024Assignee: Acuitas Therapeutics, Inc.Inventors: Xinyao Du, Steven M. Ansell, Jason Samuel Tan, Polina Blagojevic, Stephen Paul Arns, Julia Gatenyo
-
Patent number: 12065396Abstract: Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: August 17, 2018Date of Patent: August 20, 2024Assignee: Acuitas Therapeutics, Inc.Inventor: Xinyao Du
-
Patent number: 11976019Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: July 16, 2021Date of Patent: May 7, 2024Assignee: Acuitas Therapeutics, Inc.Inventors: Julia Gatenyo, Xinyao Du
-
Patent number: 11820728Abstract: Compounds are provided having one of the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: April 27, 2018Date of Patent: November 21, 2023Assignee: Acuitas Therapeutics, Inc.Inventors: Xinyao Du, Steven M. Ansell
-
Patent number: 11712481Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.Type: GrantFiled: October 26, 2017Date of Patent: August 1, 2023Assignee: Acuitas Therapeutics, Inc.Inventors: Michael J. Hope, Barbara Mui, Paulo Jia Ching Lin, Christopher J. Barbosa, Thomas D. Madden, Steven M. Ansell, Xinyao Du
-
Patent number: 11648324Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: May 11, 2021Date of Patent: May 16, 2023Assignee: Acuitas Therapeutics, Inc.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 11639329Abstract: Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: August 16, 2018Date of Patent: May 2, 2023Assignee: Acuitas Therapeutics, Inc.Inventor: Xinyao Du
-
Patent number: 11634379Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: June 19, 2020Date of Patent: April 25, 2023Assignee: Acuitas Therapeutics, Inc.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 11542225Abstract: Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G1, G1?, G2, G2?, G3, L1, L1?, L2, L2?, X, X?, Y and Y? are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: August 17, 2018Date of Patent: January 3, 2023Assignee: Acuitas Therapeutics, Inc.Inventor: Xinyao Du
-
Patent number: 11524932Abstract: Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, Y, L1, L2, L3, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: August 17, 2018Date of Patent: December 13, 2022Assignee: Acuitas Therapeutics, Inc.Inventor: Xinyao Du
-
Patent number: 11453639Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, G1, G2, and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: January 10, 2020Date of Patent: September 27, 2022Assignee: ACUITAS THERAPEUTICS, INC.Inventor: Xinyao Du
-
Patent number: 11357856Abstract: Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: April 13, 2018Date of Patent: June 14, 2022Assignee: ACUITAS THERAPEUTICS, INC.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 11168051Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: February 1, 2019Date of Patent: November 9, 2021Assignee: ACUITAS THERAPEUTICS, INC.Inventors: Xinyao Du, Steven M. Ansell
-
Publication number: 20210251898Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.Type: ApplicationFiled: January 6, 2021Publication date: August 19, 2021Applicants: CureVac AG, Acuitas Therapeutics Inc.Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
-
Patent number: 11040112Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: November 8, 2018Date of Patent: June 22, 2021Assignee: ACUITAS THERAPEUTICS, INC.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 10723692Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: September 14, 2018Date of Patent: July 28, 2020Assignee: Acuitas Therapeutics, Inc.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 10221127Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: June 29, 2016Date of Patent: March 5, 2019Assignee: Acuitas Therapeutics, Inc.Inventors: Xinyao Du, Steven M. Ansell
-
Publication number: 20190022247Abstract: Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: ApplicationFiled: December 30, 2016Publication date: January 24, 2019Applicant: Acuitas Therapeutics, Inc.Inventors: Steven M. Ansell, Xinyao Du
-
Patent number: 10166298Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.Type: GrantFiled: October 28, 2016Date of Patent: January 1, 2019Assignee: Acuitas Therapeutics, Inc.Inventors: Steven M. Ansell, Xinyao Du